Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,628 | 2,921 | 4,372 | 6,257 | 8,500 |
| Receivables | N/A | N/A | 1,250 | N/A | N/A |
| TOTAL | $2,126 | $3,378 | $5,768 | $6,906 | $8,635 |
| Non-Current Assets | |||||
| PPE Net | 263 | 287 | 60 | 69 | 76 |
| Other Non-Current Assets | 48 | 48 | 48 | 48 | 47 |
| TOTAL | $311 | $334 | $108 | $117 | $123 |
| Total Assets | $2,437 | $3,712 | $5,876 | $7,023 | $8,758 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 632 | 867 | 874 | 930 | 930 |
| Accrued Expenses | 205 | 443 | 962 | 795 | 565 |
| TOTAL | $1,005 | $1,368 | $1,872 | $1,797 | $1,602 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,825 | 1,578 | 1,339 | 1,102 | 946 |
| TOTAL | $2,039 | $1,729 | $1,415 | $1,139 | $994 |
| Total Liabilities | $3,044 | $3,096 | $3,288 | $2,936 | $2,595 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 312 | 310 | 286 | 279 | 265 |
| Common Shares | 9 | 9 | 9 | 8 | 8 |
| Retained earnings | -144,264 | -141,999 | -139,450 | -136,811 | -133,710 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $-607 | $616 | $2,589 | $4,087 | $6,163 |
| Total Liabilities And Equity | $2,437 | $3,712 | $5,876 | $7,023 | $8,758 |